EC approves commercialization of Richter's uterine fibrosis drug
Gedeon Richter Plc. announced that the European Commission (EC) has granted approval for the marketing authorization of RYEQO a novel oral treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
This decision followed a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency on May 21 and is applicable for all member states in the European Union.
"We are delighted to offer a novel, non-invasive treatment option for women suffering of debilitating symptoms of uterine fibroids," said Erik Bogsch, chairman of Gedeon Richter Plc. "Richter strives to exploit additional therapeutic advantages promised by RYEQO® and remains committed to further expand its women’s healthcare portfolio in order to improve overall quality of life for female population."
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.